Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02006407 : A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
AgesMin: 6 Years Max: 21 Years
Inclusion Criteria:

- Pediatric patients (age 6-21) who will receive cranial radiotherapy for brian tumors.
This could include but is not limited to: low grade glioma, high grade glioma (to
include grade III but not grade IV glioma), germ cell tumors, primitive
neuroectodermal tumors, craniopharyngioma, or medulloblastoma.

- Patients should, in the estimate of the treating physician, be anticipated to have a
median survival of greater than 1 year.

Exclusion Criteria:

- Patients with previous Central Nervous System (CNS) radiation or or CNS tumors that,
in the judgement of the investigators, are likely to undergo progression during or
shortly after radiotherapy are excluded.

- Patients with glioblastoma, multiforme, gliosarcoma, diffuse pontine glioma, or other
tumors presumed to have expected median survival per the investigators of less than 1

- Patients who require sedation for Magnetic Resonance Imagining (MRI)are excluded.

- Patients at risk for nephrogenic systemic sclerosis will be excluded as a safety
precaution due to the contrast used in the scans.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557